Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

As of 12 June 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 29, an EV to EBITDA of 9.02, and a PEG ratio of 0.02, indicating strong growth potential relative to its valuation.
In comparison to its peers, Supernus Pharmaceuticals has a P/E ratio of 28.132, which is slightly lower than its current ratio, suggesting it is positioned competitively within its industry. Notably, the EV to EBITDA ratio of 8.7221 for a peer indicates that Supernus may have room for improvement in operational efficiency. Despite recent stock performance trailing the S&P 500 over the year, with a return of 18.31% compared to the S&P 500's 10.26%, the overall valuation suggests that Supernus is fairly positioned in the market.